The findings from our ‘classroom-style’ training provide the ‘proof of principle’ evidence that the combination of ‘hands-on’ training from an experienced trainer and a web-based e-trainer tool is capable of delivering an acceptable level of inter-reader reproducibility for PD-L1 IHC TC scoring in NSCLC at ≥1%, ≥25% and ≥ 50% cut-offs using the VENTANA PD-L1 (SP263) assay or the Dako PD-L1 IHC PharmDx 22C3 assay. The gene discussed is CD274; the disease is non-small cell lung carcinoma.